Literature DB >> 24663253

Serum vitamin D levels may not reflect tissue-level vitamin D in sarcoidosis.

Jill Lauren Berlin1, Ghanshyam Palamaner Subash Shantha, Henry Yeager, Linda Thomas-Hemak.   

Abstract

Hypercalcemia in sarcoidosis is due to three mechanistic reasons: (1) systemic conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D by the enzyme 1-α hydroxylase produced by activated monocyte/macrophage system, (2) production of parathormone-related peptide (PTHrP) by the sarcoid granuloma, (3) tissue-level conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D by 1-αhydroxylase produced by local monocyte/macrophage system in the sarcoid granuloma. We report two cases of one proposed mechanism of hypercalcaemia in sarcoidosis (mechanism 3). Both individuals presented with sarcoidosis and 25-hydroxyvitamin D deficiency and developed symptomatic hypercalcaemia with vitamin D replacement. Given their low serum parathormone and parathormone-related peptide levels, low serum 25-hydroxy vitamin D and normal serum 1,25-dihydroxyvitamin D, the systemic 25-hydroxy vitamin D deficiency may not have reflected an increased activity of vitamin D at the local granulomatous tissue level.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24663253      PMCID: PMC3975517          DOI: 10.1136/bcr-2014-203759

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Parathyroid-hormone-related peptides. A new class of multifunctional proteins.

Authors:  T Roskams; V Desmet
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

2.  Effects of pH on potassium: new explanations for old observations.

Authors:  Peter S Aronson; Gerhard Giebisch
Journal:  J Am Soc Nephrol       Date:  2011-10-06       Impact factor: 10.121

Review 3.  Endocrine aspects of sarcoidosis.

Authors:  J L Winnacker; K L Becker; S Katz
Journal:  N Engl J Med       Date:  1968-02-22       Impact factor: 91.245

4.  Parathyroid hormone-related protein: an unusual mechanism for hypercalcemia in sarcoidosis.

Authors:  Armand Krikorian; Sapna Shah; Jay Wasman
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

5.  Parathyroid-hormone-related protein in sarcoidosis.

Authors:  H J Zeimer; T M Greenaway; J Slavin; D K Hards; H Zhou; J C Doery; A N Hunter; A Duffield; T J Martin; V Grill
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

6.  The efficiency of magnesium supplementation in patients undergoing cardiopulmonary bypass: changes in serum magnesium concentrations and atrial fibrillation episodes.

Authors:  Wojciech Dabrowski; Ziemowit Rzecki; Małgorzata Sztanke; Józef Visconti; Piotr Wacinski; Kazimierz Pasternak
Journal:  Magnes Res       Date:  2008-12       Impact factor: 1.115

Review 7.  Calcium transport in renal epithelial cells.

Authors:  P A Friedman; F A Gesek
Journal:  Am J Physiol       Date:  1993-02

8.  Malignancy-associated hypercalcaemia: resolution of controversies over vitamin D metabolism by a pathophysiological approach to the syndrome.

Authors:  D H Schweitzer; N A Hamdy; M Frölich; A H Zwinderman; S E Papapoulos
Journal:  Clin Endocrinol (Oxf)       Date:  1994-08       Impact factor: 3.478

9.  Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis.

Authors:  J S Adams; O P Sharma; M A Gacad; F R Singer
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

10.  Renal sarcoidosis with normal serum vitamin D and refractory hypercalcemia.

Authors:  Abdulkadir Unsal; Taner Basturk; Yener Koc; Tamer Sakacı; Elbis Ahbap; Aysim Ozagarı; Ayşe Sinangil Arar; Cüneyt Akgül; Mustafa Sevınc
Journal:  Int Urol Nephrol       Date:  2012-07-25       Impact factor: 2.266

  10 in total
  2 in total

Review 1.  Osseous manifestations of sarcoidosis.

Authors:  Eugeniusz Józef Kucharz
Journal:  Reumatologia       Date:  2020-04-30

Review 2.  Sarcoidosis and calcium homeostasis disturbances-Do we know where we stand?

Authors:  Łukasz Gwadera; Adam Jerzy Białas; Mikołaj Aleksander Iwański; Paweł Górski; Wojciech Jerzy Piotrowski
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.